Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey by Lombardi, Cp et al.
  
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by 
agreement between Elsevier and the University of Turin. Changes resulting from the publishing process 
- such as editing, corrections, structural formatting, and other quality control mechanisms - may not be 
reflected in this version of the text. The definitive version of the text was subsequently published in 
Surgery, 152, 6,1158-1164,2012, DOI 10.1016/j.surg.2012.08.014 
http://www.sciencedirect.com/science/article/pii/S003960601200459X 
 
 
 
 
You may download, copy and otherwise use the AAM for non-commercial purposes provided that your 
license is limited by the following restrictions: 
 
(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND 
license.  
(2) The integrity of the work and identification of the author, copyright owner, and publisher must be 
preserved in any copy.  
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), DOI 10.1016/j.surg.2012.08.014 
http://www.sciencedirect.com/science/article/pii/S003960601200459X 
 
Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) 
adrenocortical carcinoma: Results of a multiinstitutional Italian survey 
• Celestino Pio Lombardi, MDa, Marco Raffaelli, MDa, , , Carmela De Crea, MDa, Marco 
Boniardi, MDb, Giorgio De Toma, MDc, Luigi Antonio Marzano, MDd, Paolo Miccoli, 
MDe, Francesco Minni, MDf, Mario Morino, MDg, Maria Rosa Pelizzo, MDh, Andrea 
Pietrabissa, MDi, Andrea Renda, MDj, Andrea Valeri, MDk, Rocco Bellantone, MDa 
Background 
We compared the oncologic effectiveness of open adrenalectomy and endoscopic adrenalectomy in 
the treatment of patients with localized adrenocortical carcinoma. 
Methods 
One hundred fifty-six patients with localized adrenocortical carcinoma (stage I/II) who underwent 
R0 resection were included in an Italian multiinstitutional surgical survey. They were divided into 2 
groups based on the operative approach (either conventional or endoscopic). 
Results 
One hundred twenty-six patients underwent open adrenalectomy and 30 patients underwent 
endoscopic adrenalectomy. The 2 groups were well matched for age, sex, lesion size, and stage (P = 
NS). The mean follow-up time was similar for the 2 groups (P = NS). The local recurrence rate was 
19% for open adrenalectomy and 21% for endoscopic adrenalectomy, whereas distant metastases 
were recorded in 31% of patients in the conventional adrenalectomy group and 17% in the 
endoscopic adrenalectomy group (P = NS). The mean time to recurrence was 27 ± 27 months in the 
conventional open adrenalectomy group and 29 ± 33 months in the endoscopic adrenalectomy 
group (P = NS). No significant differences were found between the 2 groups in terms of 5-year 
disease-free survival (38.3% vs 58.2%) and 5-year overall survival rates (48% vs 67%; P = NS). 
Conclusion 
The operative approach does not affect the oncologic outcome of patients with 
localized adrenocortical carcinoma, if the principles of surgical oncology are respected. 
After the introduction of endoscopic adrenalectomy (EA) into clinical practice, it emerged as the 
treatment of choice for most adrenal surgical disorders.1 Most experts agree that EA is the criterion 
standard treatment for small to medium sized (≤6 cm) benign adrenal tumors, both functioning and 
nonfunctioning.1, 2 and 3 The role of EA in patients with adrenal malignancies is still controversial.4 
Open adrenalectomy (OA) is the procedure of choice for invasive adrenal cortical carcinoma 
(ACC), allowing for a large, complete, and oncologically consistent en bloc resection.5, 6 and 7 The 
increasing experience with EA and the excellent results of this procedure have led some authors to 
also propose it for large and potentially malignant adrenal tumors.4, 8, 9 and 10 Moreover, with the 
widespread diffusion of EA, the number of patients with adrenal incidentaloma referred to 
adrenalectomy has increased.11 This finding could imply a risk of unexpected diagnosis of localized 
ACC at final histology.12 Indeed, the diagnosis of ACC is frequently made in up to 10% of patients 
with adrenal incidentaloma.13 
Operative resection is of the utmost importance in the treatment of localized ACC (stage I/II) 
because margin-free complete resection is the only means to achieve long-term cure.14 Some reports 
have shown an increased risk of positive margin or tumor spill,12 peritoneal carcinomatosis,15 and 16 
and earlier recurrence12 in patients undergoing EA for localized ACC. Similar findings have led an 
international consensus conference to strongly discourage EA for the treatment of known or 
suspicious ACC.14 In contrast, recently published studies have suggested that EA could achieve 
similar results in terms of recurrence rate as OA in the case of localized ACC.8, 17, 18 and 19 While OA 
is mandatory in cases of local invasion, strong evidence to recommend or discourage the 
endoscopic approach in patients with localized ACC is lacking.8 
The aim of this study was to compare the oncologic effectiveness of OA versus EA in the treatment 
of patients with localized ACC based on a database of an Italian multiinstitutional surgical survey. 
Methods 
After the previous experience with an Italian Registry of ACC,7 and 20 a new Italian multiinstitutional 
surgical survey was started in December 2003 with the aim to evaluate the medical care of ACC 
patients and to better characterize the clinical course and the outcome of this disease in Italy.21 
A specific call was sent to the heads of Italian Surgical Divisions. After acceptance to participate by 
the center, a structured patient form specifically developed for this study was sent to collect 
comprehensive information on the diagnostic procedures, treatment, and follow-up of patients 
operated on for ACC. The completed form was sent back to the coordinating center via e-mail. 
A specific e-mail address (surrene@rm.unicatt.it) was created with this purpose. 
The patient form included detailed information about demographics, primary diagnosis (including 
functional status), imaging studies, operative and pathologic data, adjuvant treatment(s), and 
follow-up data. Participating centers were asked to complete the forms (1 per enrolled patient) after 
reviewing the medical records of the recruited patients and to provide follow-up information at the 
time of any relevant change in the course of the disease at least every 6 months. The recruitment 
and the follow-up of the included patients for this study were closed in July, 2010. All of the 
collected data were entered into a specifically designed database (Excel; Microsoft, Redmond, WA) 
by trained medical personnel. 
Study design 
Among the patients included in the survey, those who underwent radical surgery (R0 resection) for 
a localized (stage I/II) ACC were included in the present study. 
The assessment of the preoperative work-up was based on treatment guidelines of the National 
Institutes of Health (NIH) state-of-the-science statement on management of the clinically 
unapparent adrenal mass of 200222 and the recommendations from the European Network for the 
Study of Adrenal Tumors (ENSAT) on the care of ACC patients.9 
Computed tomographic (CT) scans or, alternatively, magnetic resonance imaging (MRI) scans of 
the abdomen and a CT scan of the thorax were recommended for a complete radiologic 
evaluation.9 and 22 
The postoperative stage was based on the criteria proposed by MacFarlane and revised by Sullivan 
et al.23 Overall survival (OS) for the study population was calculated from the date of the diagnosis 
to the date of the death, or to the date of the last follow-up evaluation for the patients who were still 
alive. Disease-free survival (DFS) was calculated from the date of diagnosis to the date of diagnosis 
of tumor recurrence, or to the date of last follow-up evaluation for patients without recurrence. 
Disease recurrence was diagnosed on the basis of clinical, laboratory, and radiologic evidence; 
histologic confirmation of the recurrence was not required. 
The included patients were divided in 2 groups based on the operative approach: the OA group 
(OA-G) and the EA group (EA-G). A comparative analysis between the 2 groups was performed 
and included the following parameters: patients demographics, preoperative diagnosis, functional 
status, tumor size, lymph node dissection if any, complications, hospital stay, postoperative tumor 
stage, adjuvant therapy, and follow-up results. 
Statistical analysis 
Statistical analysis was performed using SPSS software (version 10.0; SPSS Inc, Chicago, IL). 
Continuous variables were expressed in terms of mean or median (as appropriate) ± the standard 
deviation (SD), followed by the range. The χ2 test was used for categorical variables, and analyses 
of variance (ANOVAs) were used for continuous variables. OS and DFS curves were calculated 
according to the Kaplan–Meier method and were compared by means of the log-rank test. 
Regardless of the test used, P < .05 was considered significant. 
Study endpoints 
The primary endpoint was to compare the oncologic effectiveness of the open and endoscopic 
approach as evaluated by the OS and DFS. Secondary outcome assessment included the comparison 
of the mean time to recurrence and the type of recurrence (ie, local and/or distant). 
Results 
At the time that the database for this study was closed (July 2010), 278 patients were recruited. 
Among them, 156 had a R0 resection for a stage I or II ACC and were included in the present study. 
The characteristics of the study population are listed in the Table. One hundred twenty-six patients 
underwent OA (OA-G), and the remaining 30 patients underwent EA (EA-G; Table). EA was 
accomplished using the lateral transabdominal approach in 29 cases and by the posterior 
retroperitoneoscopic approach in the remaining case. No conversion to OA was necessary in 
patients who underwent EA. Among the 122 excluded patients with stage III and IV ACC, 1 male 
patient underwent laparoscopic exploration to evaluate the resectability of the lesion as the first step 
of the operative procedure. After conversion to an open procedure, adrenalectomy and nephrectomy 
and splenectomy and distal pancreatectomy were performed. He died of unrelated causes (hepatic 
failure caused by cirrhosis) 3 months after the procedures. 
Table.  
Characteristics of the study population and comparative analysis between the open 
adrenalectomy and endoscopic adrenalectomy groups 
All patients OA-G EA-G No. of patients 
156 126 30 
P 
value 
Age (yrs), mean ± SD (range) 47.7 ± 15.6 (10–81) 
46.6 ± 15.1 
(10–74) 
52.0 ± 17.0 
(26–81) .088 
Sex (male/female) 56/100 45/81 11/19 .909 
Laterality (right/left) 87/69 64/62 23/7 .018 
Preoperative diagnosis, n    
 Secreting tumor 62 58 4 
 Nonsecreting tumor 10 9 1 
 Incidentaloma 83 59 25 
.001 
Lymph node dissection 24 23 1 .079 
Operation time (min), mean ± SD 
(range) 
131 ± 57 (30–
300) 
129 ± 54 (50–
250) 
135 ± 65 (30–
300) .598 
Tumor size (mm), mean ± SD 
(range) 
83.8 ± 43.0 
(30–210) 
90.4 ± 46.3 
(30–210) 
77.3 ± 34.3 
(30–150) .147 
Tumor stage 
All patients OA-G EA-G No. of patients 
156 126 30 
P 
value 
 I 34 24 10 
 II 122 102 20 
.145 
Postoperative complications 8 7 1 .972 
Hospital stay (d), mean ± SD 
(range) 
8.1 ± 5.8 (4–
42) 
9.3 ± 6.2 (4–
42) 
5.3 ± 3.7 (2–
20) <.001 
No. who completed follow-up 134 110 24 .885 
Follow-up time (mos), mean ± SD 
(range) 
42 ± 35 (1–
192) 
40 ± 34 (1–
192) 
50 ± 37 (2–
120) .192 
Adjuvant therapy 50 41 9 
 Mitotane 18 14 4 
 Polychemotherapy 10 6 4 
 Mitotane plus polychemotherapy 22 21 1 
.832 
Recurrence 56 48 8  
 Local 18 14 4 
 Distant 30 27 3 
 Local and distant 8 7 1 
.497 
Time of recurrence (mos), mean ± 
SD (range) 
27 ± 28 (1–
115) 
27 ± 27 (1–
115) 29 ± 33 (9–87) .839 
5-yr disease-free survival 43.1% 38.3% 58.2% 
Median disease-free survival (mos) 60 48 72 
.120 
5-yr overall survival 51.5% 47.5% 66.5% 
Median overall survival (mos) 72 60 108 
.200 
EA-G, Endoscopic adrenalectomy group; OA-G, open adrenalectomy group; SD, standard 
deviation. 
 
The 2 groups were well matched for age, sex distribution, lesion size, and stage (P = NS; Table). A 
significantly greater rate of patients in the EA-G had a preoperative diagnosis of adrenal 
incidentaloma (25/30 vs 59/126), whereas the rate of secreting tumor was significantly greater in 
the OA-G (58/126 vs 4/30; P = .001; Table). 
No case of tumor fragmentation was recorded in either group. Some lymph node dissection was 
performed in 24 patients: 1 in the EA-G (3%) and 23 in the OA-G (18%; P = .079). The mean 
operative time was similar in the OA-G and the EA-G (129 ± 54 vs 135 ± 65, respectively; P = 
.598; Table). 
Postoperative complications were registered in 7 out of 126 patients in the OA-G and 1 out 30 
patients in the EA-G (P = .97). The mean hospital stay was significantly shorter in the EA-G than in 
the OA-G (5.3 ± 3.7 vs 9.3 ± 6.2; P < .001). 
The follow-up evaluation was completed in 134 patients: 110 in the OA-G and 24 in the EA-G. The 
mean follow-up time was 42 ± 35 months (range, 1–192 months): 40 ± 34 months (range, 1–192) in 
the OA-G and 50 ± 37 (range, 2–120) in the EA-G (P = .192; Table). 
The rate of patients who underwent adjuvant therapy was 37% (41/110) in the OA-G and 38% 
(9/24) in the EA-G (P = .832). 
The rate of local recurrence was 19% (21/110) and 21% (5/24) in the OA-G and in the EA-G, 
respectively. The rate of distant metastasis was 31% (34/110) in the OA-G and 17% (4/24) in the 
EA-G (P = .497). A combined pattern of recurrent disease (local recurrence and distant metastasis) 
was observed in 6% (7/110) of OA patients and 4% (1/24) of EA patients. The mean time to 
recurrence was 27 ± 27 months in the OA-G and 29 ± 33 months in the EA-G (P = .839). 
At the most recent follow-up, 34% (46/134) of the patients had died, including 41 of 110 (37%) OA 
patients and 5 of 24 (21%) EA patients (P = .194). 
The median DFS was 48 months in the OA-G and 72 months in the EA-G (P = .120). The median 
OS was 60 and 108 months for OA and EA patients, respectively (P = .200; Table). Five-year DFS 
and 5-year OS are shown in Figs 1 and 2, respectively. 
 
Fig 1.  
Five-year disease-free survival (DFS) in the open adrenalectomy (OA-G) and endoscopic 
adrenalectomy (EA-G) groups. (Color version of figure is available online.) 
Figure options 
 
Fig 2.  
Five-year overall survival (OS) in the open adrenalectomy (OA-G) and endoscopic 
adrenalectomy (EA-G) groups. (Color version of figure is available online.) 
Figure options 
Discussion 
ACC is a rare malignant tumor with an incidence of 1 to 2 million patients per year.8 ACC has a 
poor prognosis, with an overall 5-year survival rate ranging from 15% to 60% that correlates with 
disease stage at diagnosis.6, 7 and 9 In spite of recent advances in terms of adjuvant treatment, 
including mitotane and chemotherapy protocols,9 and 14 complete local excision has, until now, been 
the only curative treatment.5 and 14 Even in recurrent disease, repeat resection can positively 
influence patient outcome.20 
Thirty percent of ACCs are stage I or II at presentation.8 Tumors in these stages are confined to the 
adrenal capsule, without invasion of the surrounding tissue, adjacent organs, lymph node, or distant 
metastases. At least from a theoretic point of view, they are amenable to curative local surgical 
resection.8 For all of these reasons, a comprehensive operative procedure, respecting the oncologic 
principles of R0 en bloc resection and without tumor grasping or tumor capsule rupture, is crucial.8 
For localized neoplasms, an appropriate surgical resection should include adrenal gland and 
periadrenal fat. In spite of recent reports indicating that locoregional lymph node dissection 
may improve tumor staging and lead to a favorable oncologic outcome in patients with localized 
ACC,24 there is no precise definition of locoregional lymph node dissection and no consensus about 
its role in the management of ACC patients.8 and 9 
In contrast, early after its introduction into clinical practice, EA emerged as the treatment of choice 
for most adrenal masses1 and 2—including large and potentially malignant tumors4 and 10—because of 
its unequivocal advantages over OA in terms of postoperative recovery. In addition, it has been 
shown that after the introduction of EA, a greater percentage of patients with adrenal incidentaloma 
were selected for adrenalectomy.11 Moreover, about 10% of the resected adrenal incidentaloma 
have a pathologic diagnosis of ACC,13 and on occasion ACCs have been unknowingly removed 
using a laparoscopic approach.12 Indeed, in the absence of radiologic evidence of the invasion 
of surrounding tissues, lymph node involvement, intravenous thrombus, or distant metastases, may 
be difficult to predict malignancy in adrenal incidentaloma.13 and 22 As a consequence, the role of 
EA in the treatment of ACC has emerged as one of the most controversial and debated points in 
adrenal surgery. After early case reports describing tumor dissemination after EA,8 more recent 
reports based on single tertiary care referral center experiences determined important concerns 
about the endoscopic removal of adrenal tumors, revealing an increased risk of positive margin or 
tumor spill,12 and 15 peritoneal carcinomatosis,15 and 16 and earlier recurrence12 for EA. On the basis 
of such results, Miller et al12 concluded that “Although feasible in many cases and tempting, 
laparoscopic resection should not be attempted in patients with tumors suspicious for or known to 
be adrenocortical carcinoma.” However, similar findings should be considered in the context of 
selection bias, related to the referral of patients to a tertiary care referral center for treatment of 
recurrent disease, after initial laparoscopic surgery in other nonreferral centers.8, 12, 15 and 16 Recently 
published comparative studies based on single-center18 or multiinstitutional series19 found that the 
oncologic outcomes of localized ACC after EA could be similar to those seen after laparoscopic 
resection. 
In a study by Porpiglia et al,18 43 patients underwent operations for a stage I or II ACC at the 
author's institution or were referred after resection for postoperative management and treatment; 18 
underwent EA and 25 underwent OA. Only patients who underwent radical R0 surgery were 
included. The 3-year survival rate was 84% for patients who underwent OA and 100% for those 
who underwent EA. The recurrence rate was 64% in the open group compared to 66% in the 
laparoscopic group.18 Similarly, in a study by Brix et al19 based on data from a German ACC 
registry, 152 patients with ENSAT stage I–III ACC neoplasms measuring <10 cm were included; 
35 underwent EA and 117 underwent OA. The recurrence rate was 77% for the EA-G and 69% for 
the OA-G.19 The authors did not find any significant difference in terms of DFS or OS.19 
The results of the present study confirm such previous reports. No significant differences were 
found between the EA-G and OA-G in terms of 5-year OS and DFS rates (Table). Moreover, 
survival rates were similar to those reported in the literature for stage I and II neoplasms.6, 7 and 25 
Indeed, the 5-year survival rates for patients with localized ACC who underwent radical surgery 
have been reported to be 38% and 61%.6, 7 and 25 
A previously published study suggested that EA is associated with a significantly lesser time to 
local recurrence and a significantly greater local recurrence rate.12 Unfortunately, about 50% of the 
cases included in that paper had positive margins or intraoperative tumor rupture during EA 
compared to 18% of those who underwent OA.12 Indeed, the manipulation of the adrenal neoplasms 
with endoscopic instruments implies the theoretic risk of inadvertent tumor capsule fracture and 
tumor cell seeding, with consequent local and port site recurrence and peritoneal carcinomatosis. 
This worry is particularly true for large adrenal neoplasms and in the case of difficult dissection 
because of tumor adhesion with adjacent structures. 
However, surgical experience plays a crucial role in the oncologic results. Indeed, recent reports 
indicated that center volume and surgeon experience are of key importance for the oncologic 
outcome of patients with adrenal neoplasms.5, 21 and 25 
Conversely, in the present series, all patients underwent R0 radical surgery and a minority of them 
also underwent some lymph node dissection, with no significant difference between the EA-G and 
the OA-G (1/30 vs 23/126; P = NS). We found no significant difference in terms of mean time to 
recurrence and of type of recurrence (local versus distant) between the EA-G and the OA-G ( 
Table). As we have reported recently, 21 despite this study being multiinstitutional, most of the 
patients of the present series were treated at high-volume centers. This finding could at least in part 
explain the results obtained in terms of OS and DFS. In other words, it seems clear that the 
operative approach does not affect the prognosis of patients with stages I and II ACC if the 
principles of oncologic surgery are respected. 
In contrast, the results of the present study confirm that EA is associated with a better postoperative 
outcome. Indeed, even if complication rates were not significantly different between the 2 groups, 
EA is associated with a significantly shorter hospital stay (Table). 
Considering the well known advantages related to EA and the fact that there is no significant 
difference in terms of oncologic outcome, it is difficult to argue that large and/or potentially 
malignant adrenal masses should not undergo EA, in absence of the evidence of local invasion or 
distant metastases. Obviously, conversion to the open approach is recommended in cases where 
signs of local invasion are found or the dissection is difficult and implies the risk of tumor capsule 
rupture.8 and 10 Conversion should not be considered a defeat for the surgeon but rather a different 
way to safely accomplish the surgical procedure. 
The present study is based on a multiinstitutional retrospective survey, and this is its main 
limitation. Moreover, the follow-up is relatively short and the sample size is relatively small; 
additional series would be of great value. Prospective randomized trials on this topic are not likely 
to be performed, because the disease is rare, and most of the diagnoses in localized neoplasms are 
pathologic. Another potential bias of the present retrospective study could be related to patient 
selection for the 2 approaches. Indeed, in clinical practice, smaller tumors are selected for EA while 
locally infiltrating and metastatic tumors (stage III/IV) are selected mandatorily for OA. However, 
we included only patients with pathologically proven localized (stage I/II) ACCs who underwent 
R0 resection. This allowed for minimization of this potential selection bias, as indicated by the fact 
that no significant difference concerning tumor size and stage was found between the 2 groups 
(Table). 
In conclusion, our results suggest that in patients with stage I and II ACC, EA is not inferior to OA 
in terms of oncologic outcome. As a consequence, EA performed by experienced surgeons 
respecting the principles of radical R0 resection—without tumor capsule rupture and removing the 
periadrenal fat—is justified for large and potentially malignant adrenal masses and for selected 
cases of stage I and II ACC. OA is mandatory in cases of pre- or intraoperative evidence of adjacent 
organ invasion and lymph node involvement or distant metastases (stage III/IV ACC). 
Discussion 
Dr Paul Gauger (Ann Arbor, MI): Can you explain a little further, your study group, as it relates to 
staging, and at what point you made that determination? To Dr Miller's point, you talked about 
including only stage I and stage II tumors. Was that the preoperative stage, and when the upstaging  
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